摘要
目的探讨银杏二萜内酯葡胺(DGMI)对急性脑梗死患者血浆Ⅰ型纤溶酶原激活物抑制因子(PAI-1)水平及神经功能的影响。方法选择急性脑梗死患者80例,随机分为DGMI组与对照组,每组40例。DGMI组给予静脉滴注DGMI25 mg/d,连续治疗14 d;对照组给予无DGMI的基础治疗。比较2组治疗前、治疗14 d后神经功能缺损程度、血栓弹力图(TEG)参数、血浆PAI-1水平。结果治疗14 d后,2组美国国立卫生研究院卒中量表(NIHSS)评分与Barthel指数均优于治疗前,且DGMI组NIHSS评分与Barthel指数均优于对照组,差异有统计学意义(P<0.05)。治疗14 d后,DGMI组TEG中R值与K值均较治疗前升高,Angel角与MA值均较治疗前降低,差异有统计学意义(P<0.05);对照组治疗后MA值与治疗前比较,差异有统计学意义(P<0.05);DGMI组R值与K值均高于对照组,Angel角与MA值均低于对照组,差异有统计学意义(P<0.05)。治疗后,DGMI组血浆PAI-1水平降低,且低于对照组,差异有统计学意义(P<0.05)。结论DGMI可能通过调控血浆PAI-1的水平来影响凝血与纤维溶解系统的活性,进而改善患者的神经功能缺损症状。
Objective To explore the effect of diterpene ginkgolides meglumine injection(DGMI)on the level of plasma typeⅠplasminogen activator inhibitor(PAI-1)and neurological function in patients with acute cerebral infarction.Methods Eighty patients with acute cerebral infarction were selected and randomly divided into DGMI group and control group,with 40 cases in each group.The DGMI group was treated with intravenous infusion of DGMI for 25 mg per day for 14 days,while the control group was given basic treatment without DGMI.The degree of neurological deficit,parameters of thromboelastography(TEG)and plasma PAI-1 level were compared between the two groups before and after 14 days of treatment.Results After 14 days of treatment,the National Institutes of Health Stroke Scale(NIHSS)score and Barthel index in both groups were significantly better than those before treatment,and the NIHSS score and Barthel index of the DGMI group were significantly better than those of the control group(P<0.05).After 14 days of treatment,the R value and K value of TEG in the DGMI group were significantly higher than those before treatment,while degree of Angel and MA value were significantly lower than those before treatment(P<0.05).After treatment,the MA value in the control group showed significant difference when compared to treatment before(P<0.05).The R value and K value of the DGMI group were significantly higher than those of the control group,while the degree of Angel and MA value were significantly lower than those of the control group(P<0.05).After treatment,the plasma PAI-1 level in the DGMI group was significantly lower than that treatment before and the control group(P<0.05).Conclusion DGMI may affect the activity of coagulation and fibrinolysis system by regulating the plasma level of PAI-1,thereby improving the symptoms of neurological deficit in patients.
作者
周永
陈锐
支中文
赵连东
ZHOU Yong;CHEN Rui;ZHI Zhongwen;ZHAO Liandong(Huai’an Hospital Affiliated to Xuzhou Medical University,Huai’an City Second People’s Hospital,Huai'an,Jiangsu,223000)
出处
《实用临床医药杂志》
CAS
2020年第19期90-92,96,共4页
Journal of Clinical Medicine in Practice
基金
江苏省淮安市市级科技计划专项资金(HAB2019032)。
关键词
银杏二萜内酯葡胺
血浆Ⅰ型纤溶酶原激活物抑制因子
急性脑梗死
血栓弹力图
神经功能缺损
diterpene ginkgolides meglumine injection
plasma type I plasminogen activator inhibitor
acute cerebral infarction
thromboelastography
neurological deficit
